LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

0.32 -8.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.31

Max

0.35

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+1157.14% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-18M 88M
Eelmine avamishind	8.89
Eelmine sulgemishind	0.32

Uudiste sentiment

By Acuity

50%

153 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. märts 2026, 17:33 UTC

Uudisväärsed sündmused

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. märts 2026, 17:00 UTC

Uudisväärsed sündmused

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. märts 2026, 16:03 UTC

Uudisväärsed sündmused

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Rising Inflation Fears -- Market Talk

29. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29. märts 2026, 23:23 UTC

Market Talk

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29. märts 2026, 22:34 UTC

Market Talk

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29. märts 2026, 22:09 UTC

Market Talk

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29. märts 2026, 21:06 UTC

Market Talk

Uudisväärsed sündmused

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29. märts 2026, 21:03 UTC

Market Talk

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29. märts 2026, 21:01 UTC

Market Talk

Uudisväärsed sündmused

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29. märts 2026, 09:30 UTC

Omandamised, ülevõtmised, äriostud

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28. märts 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 19:16 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. märts 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. märts 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. märts 2026, 19:03 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 19:02 UTC

Market Talk

Uudisväärsed sündmused

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. märts 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. märts 2026, 17:36 UTC

Uudisväärsed sündmused

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. märts 2026, 17:34 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. märts 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. märts 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. märts 2026, 16:32 UTC

Market Talk

Uudisväärsed sündmused

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 15:43 UTC

Market Talk

Uudisväärsed sündmused

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

1157.14% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 1157.14%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

153 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.